TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 24170679

Group type: EXPERIMENTAL
Intervention: Qigong
Number of subjects: 40

Group type: COMPARATOR
Intervention: Stretching
Number of subjects: 40
Study: 22485048

Group type: EXPERIMENTAL
Intervention: ACWY-TT alone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Coad (ACWY-TT with seasonal influenza vaccine)
Number of subjects: 0

Group type: COMPARATOR
Intervention: MenPS alone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 0
Study: 20331579

Group type: EXPERIMENTAL
Intervention: 5 apheresis treatments
Number of subjects: 196

Group type: EXPERIMENTAL
Intervention: 10 apheresis treatments
Number of subjects: 196
Study: 17363187

Group type: EXPERIMENTAL
Intervention: Breast radiotherapy + boost (n = 414)
Number of subjects: 869

Group type: COMPARATOR
Intervention: No breast radiotherapy (n = 417)
Number of subjects: 869
Study: 17043073

Group type: EXPERIMENTAL
Intervention: LV-Epi pacing
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Bi-V pacing
Number of subjects: 36

Group type: COMPARATOR
Intervention: RV-Endo pacing
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Follow-up observations
Number of subjects: 36
Study: 12900242

Group type: EXPERIMENTAL
Intervention: Er:YAG laser treatment for 3+ cataracts
Number of subjects: 147

Group type: EXPERIMENTAL
Intervention: Er:YAG laser treatment for 4+ cataracts
Number of subjects: 147

Group type: COMPARATOR
Intervention: Ultrasound treatment for all cataract densities
Number of subjects: 147
Study: 10919019

Group type: EXPERIMENTAL
Intervention: Laser combined with percutaneous radiotherapy (group 1)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Self-expanding metal stent (group 2)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Self-expanding metal stent with initial laser therapy (group 2a)
Number of subjects: 39
Study: 8731468

Group type: EXPERIMENTAL
Intervention: Piagetian principles training
Number of subjects: 25

Group type: COMPARATOR
Intervention: Common population pool
Number of subjects: 25
Study: 1358674

Group type: EXPERIMENTAL
Intervention: Turbohaler (T)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Diskhaler (D)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Both inhalers
Number of subjects: 36
Study: 6143970

Group type: EXPERIMENTAL
Intervention: Active pulsed magnetic field stimulators
Number of subjects: 16

Group type: COMPARATOR
Intervention: Dummy pulsed magnetic field stimulators (Control)
Number of subjects: 16
Study: 30621948

Group type: EXPERIMENTAL
Intervention: Women with HFrEF
Number of subjects: 13500

Group type: COMPARATOR
Intervention: Device therapy in women
Number of subjects: 13500
Study: 29526837

Group type: EXPERIMENTAL
Intervention: Core and mobility training (EG; n=8) - 2 weekly sessions of 50 minutes for 10 weeks
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control group (CG; n=16) - received ergonomic guidelines but no core and mobility training
Number of subjects: 24

Group type: COMPARATOR
Intervention: Comparison between EG and CG post-intervention
Number of subjects: 24
Study: 26681684

Group type: EXPERIMENTAL
Intervention: Concurrent radiotherapy with letrozole (arm A)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Sequential radiotherapy with letrozole (arm B)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Both arms (A and B)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Patients with grade ≥2 RISF
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Patients with identified SNPs
Number of subjects: 150
Study: 25194287

Group type: EXPERIMENTAL
Intervention: Strategy of adjusting therapy to achieve and maintain a target NT-proBNP level of <1,000 pg/ml
Number of subjects: 1100

Group type: COMPARATOR
Intervention: Usual care (optimized guideline-recommended therapy)
Number of subjects: 1100
Study: 22762346

Group type: EXPERIMENTAL
Intervention: DHEP-heparin plaster
Number of subjects: 331

Group type: EXPERIMENTAL
Intervention: DHEP plaster
Number of subjects: 331

Group type: COMPARATOR
Intervention: Placebo plaster
Number of subjects: 331
Study: 20573405

Group type: EXPERIMENTAL
Intervention: 375µg interferon (IFN)‐β‐1b
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: 250µg interferon (IFN)‐β‐1b
Number of subjects: 37

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 37
Study: 17659926

Group type: EXPERIMENTAL
Intervention: Atorvastatin 10 mg
Number of subjects: 191

Group type: EXPERIMENTAL
Intervention: Atorvastatin 20 mg
Number of subjects: 191

Group type: EXPERIMENTAL
Intervention: Atorvastatin 40 mg
Number of subjects: 191

Group type: EXPERIMENTAL
Intervention: Atorvastatin 80 mg
Number of subjects: 191
Study: 16282294

Group type: EXPERIMENTAL
Intervention: Mosquito nets treated with lambda-cyhalothrin
Number of subjects: 432
Study: 12022323

Group type: EXPERIMENTAL
Intervention: Etanercept
Number of subjects: 51

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51
Study: 10362152

Group type: EXPERIMENTAL
Intervention: Methotrexate, 50 mg/m2
Number of subjects: 27

Group type: COMPARATOR
Intervention: 6‐mercaptopurine, 200 mg
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Methotrexate
Number of subjects: 27
Study: 7739158

Group type: EXPERIMENTAL
Intervention: 123I-BMIPP imaging
Number of subjects: 25
Study: 1838561

Group type: EXPERIMENTAL
Intervention: GULin vocoder
Number of subjects: 13

Group type: COMPARATOR
Intervention: CIDLog vocoder
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: CIDLin vocoder
Number of subjects: 13

Group type: COMPARATOR
Intervention: Visual-only control
Number of subjects: 13

Group type: COMPARATOR
Intervention: Vocoder control
Number of subjects: 13
Study: 6804241

Group type: EXPERIMENTAL
Intervention: Indomethacin
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Aspirin
Number of subjects: 59

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 59
Study: 30882641

Group type: EXPERIMENTAL
Intervention: Multimodal intervention involving nurses (reinforcing knowledge on antibiotics and UTI, decision aid diagram, communication skills improvement, increased involvement in prescription process).
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (standard care without the multimodal intervention).
Number of subjects: 40
Study: 27558855

Group type: EXPERIMENTAL
Intervention: Cuff position at the most distal location
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Cuff position at the distal part
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Proximal lower leg
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Staircase pattern
Number of subjects: 20
Study: 26921746

Group type: EXPERIMENTAL
Intervention: Losartan (12.5 mg twice per day for the 1st week, 25 mg twice per day during the 2nd week, and 75 mg/d from the 3rd week to the end of the 16th week)
Number of subjects: 73

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 73
Study: 25073453

Group type: EXPERIMENTAL
Intervention: SINGLE training condition
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: FIXED training condition
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: VARIABLE training condition
Number of subjects: 42
Study: 23074234

Group type: EXPERIMENTAL
Intervention: Intensive i.v. insulin therapy (BG = 70-110 mg/dl)
Number of subjects: 93

Group type: COMPARATOR
Intervention: Standard s.c. insulin therapy (BG = 70-180 mg/dl)
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Intensive i.v. insulin therapy
Number of subjects: 93

Group type: COMPARATOR
Intervention: Standard s.c. insulin therapy
Number of subjects: 93
Study: 18678766

Group type: EXPERIMENTAL
Intervention: Exemestane (n=77)
Number of subjects: 142

Group type: COMPARATOR
Intervention: Tamoxifen (n=65)
Number of subjects: 142
Study: 17538940

Group type: EXPERIMENTAL
Intervention: Self-monitoring of blood glucose (SMBG)
Number of subjects: 1000
Study: 15898439

Group type: EXPERIMENTAL
Intervention: Exchange of cerebrospinal fluid and small dose of urokinase injection
Number of subjects: 134

Group type: COMPARATOR
Intervention: Exchange of cerebrospinal fluid
Number of subjects: 134
Study: 12472706

Group type: EXPERIMENTAL
Intervention: Diclofenac suppositories (approximately 1 mg x kg(‐1))
Number of subjects: 40

Group type: COMPARATOR
Intervention: No treatment (Control)
Number of subjects: 40
Study: 9824788

Group type: EXPERIMENTAL
Intervention: High-dose oral ganciclovir (6,000 mg/day)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Ganciclovir 2,000 mg every 8 hours alone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ganciclovir 2,000 mg every 8 hours in combination with didanosine 200 mg every 12 hours
Number of subjects: 0
Study: 7982639

Group type: EXPERIMENTAL
Intervention: Type 2 hepatitis C virus
Number of subjects: 98

Group type: COMPARATOR
Intervention: Other genotypes
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Type 1 hepatitis C virus
Number of subjects: 98
Study: 2732807

Group type: EXPERIMENTAL
Intervention: RRR‐alpha‐tocopherol 600 mg (900 IU) daily for 12 weeks
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo capsules
Number of subjects: 19
Study: 31955410

Group type: EXPERIMENTAL
Intervention: mHealth measures of heart rate (HR)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: mHealth measures of blood pressure (BP)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: bisoprolol
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: salbutamol
Number of subjects: 18

Group type: COMPARATOR
Intervention: no treatment
Number of subjects: 18
Study: 31662385

Group type: EXPERIMENTAL
Intervention: Hybrid cardiac rehabilitation programme (10 supervised exercise sessions and individualised lifestyle counselling, transitioning to unsupervised delivery via text messages and phone calls after 4-6 weeks)
Number of subjects: 308

Group type: COMPARATOR
Intervention: Standard cardiac rehabilitation programme (18-22 supervised exercise sessions and group education sessions about lifestyle)
Number of subjects: 308

Group type: EXPERIMENTAL
Intervention: Hybrid cardiac rehabilitation programme
Number of subjects: 308
Study: 28383338

Group type: EXPERIMENTAL
Intervention: Cardiac rehabilitation program (8 sessions over 8 weeks)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 100
Study: 25652127

Group type: COMPARATOR
Intervention: Dihydroartemisinin-piperaquine (DP)
Number of subjects: 600

Group type: COMPARATOR
Intervention: No chemoprevention
Number of subjects: 600

Group type: COMPARATOR
Intervention: Monthly sulphadoxine-pyrimethamine (SP)
Number of subjects: 600

Group type: COMPARATOR
Intervention: Daily trimethoprim-sulphamethoxazole (TS)
Number of subjects: 600
Study: 23623865

Group type: EXPERIMENTAL
Intervention: Vaccine (two enteric-coated tablets consisting of no less than 4.5 log10 TCID50 of live ADV-4 or ADV-7)
Number of subjects: 4040

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4040

Group type: EXPERIMENTAL
Intervention: Vaccine
Number of subjects: 4040
Study: 21521008

Group type: EXPERIMENTAL
Intervention: Coblator (group A)
Number of subjects: 79

Group type: COMPARATOR
Intervention: Laser tonsillotomy (group B)
Number of subjects: 79

Group type: COMPARATOR
Intervention: Radiofrequency (group C)
Number of subjects: 79
Study: 19794312

Group type: EXPERIMENTAL
Intervention: Group 1: 1700-kcal diet (21% proteins, 27% lipids, 52% carbohydrates), cognitive-behavioural therapy (CBT), sertraline (50-150 mg/day), topiramate (25-150 mg/day)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Group 2: 1700-kcal diet (21% proteins, 27% lipids, 52% carbohydrates), cognitive-behavioural therapy (CBT), sertraline (50-150 mg/day)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Group 3: Nutritional counselling and CBT
Number of subjects: 30
Study: 16954722

Group type: EXPERIMENTAL
Intervention: Atazanavir/ritonavir (300/100 mg once daily)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Lopinavir/ritonavir (400/100 mg twice daily)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Atazanavir/ritonavir
Number of subjects: 26

Group type: COMPARATOR
Intervention: Lopinavir/ritonavir
Number of subjects: 26
Study: 15350578

Group type: EXPERIMENTAL
Intervention: Ultrasound only
Number of subjects: 593

Group type: COMPARATOR
Intervention: Ultrasound and abdominal computed tomography
Number of subjects: 593

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 593
Study: 15286319

Group type: EXPERIMENTAL
Intervention: Primary stent placement
Number of subjects: 279

Group type: COMPARATOR
Intervention: Primary angioplasty followed by selective stent placement
Number of subjects: 279
Study: 10765860

Group type: EXPERIMENTAL
Intervention: Celay inlays
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Cerec inlays
Number of subjects: 17

Group type: COMPARATOR
Intervention: Both Celay and Cerec inlays
Number of subjects: 17
Study: 7781455

Group type: EXPERIMENTAL
Intervention: Chest pain group
Number of subjects: 0

Group type: COMPARATOR
Intervention: Controls
Number of subjects: 0

Group type: COMPARATOR
Intervention: Dysphagia group
Number of subjects: 0

Group type: COMPARATOR
Intervention: Controls and Dysphagia group
Number of subjects: 0
Study: 2079570

Group type: EXPERIMENTAL
Intervention: Recombinant interferon alfa‐2a at a dose of 4.5 million units thrice weekly for 4 months
Number of subjects: 82

Group type: COMPARATOR
Intervention: No treatment (Control)
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Recombinant interferon alfa‐2a
Number of subjects: 82
Study: 492626

Group type: EXPERIMENTAL
Intervention: Ibuprofen (400 mg)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Propoxyphene (64 mg)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study: 31815370

Group type: EXPERIMENTAL
Intervention: Vitamin D 400 IU/day
Number of subjects: 196

Group type: EXPERIMENTAL
Intervention: Vitamin D 800 IU/day
Number of subjects: 196

Group type: COMPARATOR
Intervention: Conventional therapy only (control)
Number of subjects: 196
Study: 31488190

Group type: EXPERIMENTAL
Intervention: Caffeine 6 mg/kg
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Caffeine 9 mg/kg
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Caffeine 3 mg/kg
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Caffeine 9 mg/kg (consumers)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Caffeine 6 mg/kg (non-consumers)
Number of subjects: 22
Study: 28291185

Group type: EXPERIMENTAL
Intervention: Surgical-site injection containing ropivacaine, epinephrine, and morphine
Number of subjects: 102

Group type: COMPARATOR
Intervention: Control group (no injection)
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Surgical-site injection
Number of subjects: 102
Study: 26014344

Group type: EXPERIMENTAL
Intervention: Slow oscillatory transcranial direct current stimulation (0.75 Hz) during stage 2 of non-rapid eye movement sleep
Number of subjects: 6

Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 6
Study: 24740134

Group type: EXPERIMENTAL
Intervention: AB103 high-dose (0.5 mg/kg)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: AB103 low-dose (0.25 mg/kg)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: AB103 high-dose
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: AB103 low-dose
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: AB103 (both doses)
Number of subjects: 43
Study: 22995588

Group type: EXPERIMENTAL
Intervention: Intensity Modulated Radiation Therapy (IMRT)
Number of subjects: 616

Group type: COMPARATOR
Intervention: Two-Dimensional Conventional Radiation Therapy (2D‐CRT)
Number of subjects: 616
Study: 19083247

Group type: EXPERIMENTAL
Intervention: 90-min standardized task of correcting a text on a word-processor with monetary reward for productivity
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: 90-min standardized task of correcting a text on a word-processor
Number of subjects: 28
Study: 18085144

Group type: EXPERIMENTAL
Intervention: Ear point taping and pressing therapy
Number of subjects: 114

Group type: COMPARATOR
Intervention: Western medication (Indomeixin enteric tablets)
Number of subjects: 114
Study: 15129731

Group type: EXPERIMENTAL
Intervention: Fish oil (4 g daily)
Number of subjects: 83

Group type: COMPARATOR
Intervention: Olive oil (4 g daily)
Number of subjects: 83
Study: 12358303

Group type: EXPERIMENTAL
Intervention: Timolol
Number of subjects: 5

Group type: COMPARATOR
Intervention: Saline
Number of subjects: 5

Group type: COMPARATOR
Intervention: Betaxolol
Number of subjects: 5
Study: 9697664

Group type: EXPERIMENTAL
Intervention: Paricalcitol (0.04 microg/kg, increased by 0.04 microg/kg every 2 weeks to a maximum of 0.24 microg/kg)
Number of subjects: 78

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 78
Study: 7924122

Group type: EXPERIMENTAL
Intervention: Zidovudine coadministered with valproic acid
Number of subjects: 6
Study: 2681509

Group type: EXPERIMENTAL
Intervention: Acetylsalicylic acid (ASA) 100 mg daily
Number of subjects: 293

Group type: EXPERIMENTAL
Intervention: Acetylsalicylic acid (ASA) 1000 mg daily
Number of subjects: 293

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 293
Study: 31216027

Group type: EXPERIMENTAL
Intervention: High-dose PNE (N=20)
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Low-concentrated dose PNE (N=20)
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Diluted low-dose PNE (N=20)
Number of subjects: 77

Group type: COMPARATOR
Intervention: Control treatment (N=17)
Number of subjects: 77
Study: 30641350

Group type: EXPERIMENTAL
Intervention: Intravenous ketamine (0.1, 0.2, 0.5, and 1.0 mg/kg)
Number of subjects: 99

Group type: COMPARATOR
Intervention: Active placebo (intravenous midazolam)
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Intravenous ketamine
Number of subjects: 99
Study: 28380474

Group type: EXPERIMENTAL
Intervention: Triple uterine tourniquet
Number of subjects: 48

Group type: COMPARATOR
Intervention: Single uterine tourniquet
Number of subjects: 48
Study: 26561332

Group type: EXPERIMENTAL
Intervention: RAISE protocol (Randomized controlled trial to Assess Immunoglobulin plus Steroid Efficacy for Kawasaki disease)
Number of subjects: 108

Group type: COMPARATOR
Intervention: Conventional Intravenous immunoglobulin (IVIG) protocol
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Positive group (patients with positive anti-YPT and/or anti-YPM antibodies)
Number of subjects: 108

Group type: COMPARATOR
Intervention: Negative group (patients without positive anti-YPT and/or anti-YPM antibodies)
Number of subjects: 108
Study: 24745199

Group type: EXPERIMENTAL
Intervention: 9-day accommodation protocol
Number of subjects: 12

Group type: COMPARATOR
Intervention: No accommodation protocol (control)
Number of subjects: 12
Study: 22333128

Group type: EXPERIMENTAL
Intervention: Right ventricle Tei index in HAHD patients
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Pulmonary arterial systolic pressure in HAHD patients
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Serum NT-proBNP level in HAHD patients
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Pulmonary arterial systolic pressure in mild pulmonary hypertension HAHD patients
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Tei index in mild pulmonary hypertension HAHD patients
Number of subjects: 34
Study: 19835116

Group type: EXPERIMENTAL
Intervention: Acupuncture at Zhongwan (CV 12) and Si-guan points combined with reinforcing-reducing manipulation of respiration
Number of subjects: 120

Group type: COMPARATOR
Intervention: Oral administration of Fluoxetine Hydrochloride at 20 mg daily
Number of subjects: 120
Study: 17767724

Group type: EXPERIMENTAL
Intervention: 1-year moderate-to-vigorous intensity aerobic and strength training exercise programme
Number of subjects: 189

Group type: COMPARATOR
Intervention: Control group maintaining habitual exercise pattern
Number of subjects: 189
Study: 15063441

Group type: EXPERIMENTAL
Intervention: Potassium canrenoate (intravenous)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 13
Study: 11811349

Group type: EXPERIMENTAL
Intervention: Nursing intervention based on Orem's self-care theory
Number of subjects: 134

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 134
Study: 10215436

Group type: EXPERIMENTAL
Intervention: Tamoxifen treatment
Number of subjects: 211
Study: 7804020

Group type: EXPERIMENTAL
Intervention: Alcohol abuse (disease concept)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cocaine abuse (sin conception)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cigarette smoking (habit conception)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: All three substance types (sin conception)
Number of subjects: 0
Study: 3132668

Group type: EXPERIMENTAL
Intervention: Cefoxitin with doxycycline
Number of subjects: 62

Group type: COMPARATOR
Intervention: Clindamycin with amikacin
Number of subjects: 62
Study: 31333258

Group type: EXPERIMENTAL
Intervention: Active-learning sessions incorporated into the pharmacology course
Number of subjects: 0
Study: 28376966

Group type: EXPERIMENTAL
Intervention: Distribution of a multimedia disk regarding injury victims
Number of subjects: 1584

Group type: EXPERIMENTAL
Intervention: Distribution of safety brochures
Number of subjects: 1584

Group type: EXPERIMENTAL
Intervention: Mailing to parents from schools discussing the risk of fireworks and limiting the fireworks budget
Number of subjects: 1584

Group type: EXPERIMENTAL
Intervention: Peer-to-peer education by trained students about the risks of fireworks
Number of subjects: 1584

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 1584
Study: 25966132

Group type: EXPERIMENTAL
Intervention: Concurrent radiochemotherapy
Number of subjects: 40

Group type: COMPARATOR
Intervention: Traditional radiotherapy
Number of subjects: 40
Study: 23386053

Group type: EXPERIMENTAL
Intervention: 0.3% ropivacaine infusion at 4 mL/h for 64 hours
Number of subjects: 200

Group type: COMPARATOR
Intervention: Normal saline (control)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: 0.3% ropivacaine infusion
Number of subjects: 200
Study: 21574787

Group type: EXPERIMENTAL
Intervention: Q500 (500 mg quercetin·day(‐1))
Number of subjects: 941

Group type: EXPERIMENTAL
Intervention: Q1000 (1000 mg quercetin·day(‐1))
Number of subjects: 941

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 941

Group type: EXPERIMENTAL
Intervention: Q500 and Q1000
Number of subjects: 941
Study: 17272998

Group type: EXPERIMENTAL
Intervention: Esomeprazole 40 mg intravenously
Number of subjects: 28

Group type: COMPARATOR
Intervention: Pantoprazole 40 mg intravenously as infusion
Number of subjects: 28

Group type: COMPARATOR
Intervention: Pantoprazole 40 mg intravenously as bolus injection
Number of subjects: 28